The Asia-Pacific neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). China, India, and Japan, are the key economies contributing to the Asia-Pacific neurological disorder drugs industry growth. The key factors that primarily drive the market growth include the rising prevalence of neurological disorders and key contributions by the key players.
Asia-Pacific has a potential market due to the increasing R&D and investments by big pharmaceutical companies in novel drug development and innovation. The rising elder population over 65 years of age is the prime factor that creates scope for the growth of the Asia-Pacific neurological disorder drugs market as this population pool is at high risk of developing neurological disorders such as Parkinson’s Disease, and Alzheimer’s Disease.
To Request a Sample of our Report on Asia-Pacific Neurological Disorder Drugs Market: https://www.omrglobal.com/request-sample/asia-pacific-neurological-disorder-drugs-market
As per the World Bank 2019, Japan has around 28.0% geriatric population, China has 11.4%, Thailand has 12.4%, Singapore has 12.4%, while India has a total of 6.4% population aged 65 and over. As elder people are more prone to diseases, hence, creates a wide scope for the market growth in the region.
Besides, the presence of the key players such as Cadila Healthcare Ltd., Astellas Pharma Ltd., and Cipla Ltd., among others are also contributing to the growth of the market.
Market Coverage
- Market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Disorder Type
- Region Covered- Asia-Pacific
- Competitive Landscape- Cadila Healthcare Ltd., Astellas Pharma Ltd., Cipla Ltd., Sun Pharmaceuticals Industries ltd., Teva Pharmaceuticals Industries Ltd., and Takeda Pharmaceutical Co., Ltd.
A full Report of Asia-Pacific Neurological Disorder Drugs Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-neurological-disorder-drugs-market
Asia-Pacific Neurological Disorder Drugs Market – Segmentation
By Disorder Type
- Epilepsy
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Huntington Disease
- Others
Asia-Pacific Neurological Disorder Drugs Market – Countries Covered
- China
- India
- Japan
Rest of Asia-Pacific
Company Profiles
- Alembic Pharmaceuticals Ltd.
- Overview
- Alembic Pharmaceuticals in Neurological Disorder Drug Landscape
- Recent Developments
- Astellas Pharma Inc.
- AstraZeneca Plc
- Cadila Healthcare Ltd.
- Cipla Ltd.
- Daiichi Sankyo Espha Co., Ltd.
- Eisai Co. Ltd.
- GlaxoSmithKline Plc
- Novartis International AG
- Otsuka Pharmaceutical Co., Ltd.
- Pfizer Inc.
- Rusan Pharma Ltd.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co., Ltd.
- Teva Pharmaceutical Industries Ltd.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
